TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) on Monday said it would start selling the injectable formulation of its novel antibiotic Taigexyn in China next year after the manufacturer passed the Chinese regulators’ on-site inspection.
The Chinese National Medical Products Administration’s Center for Drug Evaluation began its inspection at Zhejiang Medicine Co Ltd’s (ZMC, 浙江醫藥) factory on Friday.
The Chinese pharmaceutical firm, a partner of TaiGen’s unit in Beijing, is to manufacture and market the injectable antibiotic in China.
The center finished its inspection yesterday, announcing that it had found no major errors after it examined the equipment, production process, quality control program, the ingredients and tested some samples, TaiGen said in a statement.
The center “gave us some suggestions to tweak production. Overall, it can be said that the factory passed the inspection,” TaiGen communication manager Grace Wang (王暄茹) said by telephone.
As on-site inspections marks the final stage of new drug application in China, the company is expected to receive marketing approval soon and launch sales next year, Wang said.
The approval would enable TaiGen to expand its Taigexyn production line, offering doctors an option besides the oral version of Taigexyn that it began selling in 2016, she said.
“We found that doctors prefer prescribing the oral versions of antibiotics for patients with less severe symptoms, as they can take the tablets themselves,” Wang said.
The injectable version of Taigexyn is forecast to be used for inpatient treatment or for patients with severe symptoms, she said.
The sales of oral Taigenxyn in Taiwan in the first nine months of the year surged 250 percent from a year earlier, while making an annual gain of 170 percent in China, the company’s data showed.
Sales of injectable version are expected to generate higher profits, as its price would be at least eight times more than the tablets, Wang said.
As it might take some time for the new drug to be included in China’s public health insurance program, Chinese might have to pay for the drug themselves, she added.
TaiGen said it is also seeking market approval for the intravenous formulation from Taiwan’s Food and Drug Administration and submitted a new drug application on Oct. 16.
It is difficult to forecast how long the agency’s review will take, the company said.
TaiGen shares yesterday fell 0.81 percent to NT$18.35 in Taipei trading. They have risen 7.94 percent this year.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure